Targeting proteins to improve treatment for aggressive brain cancer
Official title: Targeting scaffolding proteins to disrupt radioresistance in glioblastoma
Funded at Upstate Medical University · NIH-10975997 · Data updated 2026-11-12
This study is looking at ways to make radiation therapy work better for people with glioblastoma, a tough type of brain cancer, by targeting the special cells that help the tumor survive and resist treatment.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Upstate Medical University NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $448,250 |
| NIH project number | 1R21NS139236-01 |
| Project ID | NIH-10975997 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are experiencing treatment resistance.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research focuses on glioblastoma, a highly aggressive brain cancer that often becomes resistant to standard treatments. The project aims to disrupt the survival mechanisms of glioblastoma stem-like cells, which are responsible for the tumor's resilience. By targeting specific cell-scaffolding proteins that these cells rely on, the researchers hope to enhance the effectiveness of radiation therapy. This innovative approach seeks to create vulnerabilities in the cancer cells, potentially leading to better treatment outcomes for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in targeting similar cellular mechanisms in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
-
Upstate Medical University
Syracuse, United States Active
Researchers
- Principal investigator: Viapiano, Mariano Sebastian — Upstate Medical University
- Study coordinator: Viapiano, Mariano Sebastian
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.